Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02586051 · ClinicalTrials.gov registry record · Phase 1
A Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting Transplantation
A Phase 1 study of Kidney Failure, Chronic, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 9
- Study locations
NCT02586051: Completed Phase 1 study of Kidney Failure, Chronic, sponsored by Hoffmann-La Roche.
NCT02586051 is a Phase 1 study of Kidney Failure, Chronic that has completed, run by Hoffmann-La Roche. The registered enrollment target is 24 participants, below the 331-participant average among 23 other Kidney Failure, Chronic trials with a reported enrollment target (93% lower). The trial reports 9 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02586051, a Phase 1 study of Kidney Failure, Chronic, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a Phase Ib, open-label study of single and repeat doses of obinutuzumab administered as intravenous (IV) infusion in adults with end stage renal disease (ESRD). Participants will be enrolled into two cohorts receiving either one (Cohort 1) or two or more (Cohort 2) obinutuzumab infusions. Both cohorts will receive standard pretreatments to reduce the risk of infusion-related reactions (IRRs). Desensitization Period: In Cohort 1, participants will receive single dose obinutuzumab IV infusion on Day 1. Following review of Cohort 1 aggregated safety data up to 4 weeks post dose for the last participant of Cohort 1, Cohort 2 will be allowed to proceed. In Cohort 2, participants will receive obinutuzumab IV infusion on Days 1 and 15. Transplantation Period: Participants who qualify for transplantation and receive a compatible kidney offer after inclusion in Cohort 1 or Cohort 2 will receive two additional infusions (one at the time of transplantation and second at Week 24 post-transplantation) of obinutuzumab. Assessment of the safety and tolerability of the obinutuzumab regimen will be conducted at Week 24 of the desensitization phase and at Week 28 post-transplantation. All participants will be monitored for a minimum of 12 months following the last obinutuzumab infusion.
Conditions Studied
Interventions
- DRUG Obinutuzumab
- DRUG Intravenous Immunoglobulin
Study Locations (9)
California
- Cedars-Sinai Medical Center - Los Angeles
- UCSF - San Francisco
- Stanford Health Care - Stanford
Minnesota
- Mayo Clinic - Minnesota - Rochester
- Mayo Clinic - Rochester
Ohio
- The Christ Hospital - Cincinnati
- University of Cincinnati College of Medicine - Cincinnati
Maryland
- Johns Hopkins Hospital - Baltimore
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-11-19 |
| Est. Completion | 2018-11-26 |
| Phase | Phase 1 |
What the finished NCT02586051 record still lists
NCT02586051 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 331-participant average among 23 other Kidney Failure, Chronic trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Kidney Failure, Chronic appearing as the primary indexed condition, and to 2 interventions - of which Obinutuzumab is the first listed.
NCT02586051 lists 9 locations in 5 states (California, Minnesota, Ohio).
Frequently Asked Questions
What is clinical trial NCT02586051 about?
NCT02586051 is a clinical study titled "A Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting Transplantation". This is a Phase Ib, open-label study of single and repeat doses of obinutuzumab administered as intravenous (IV) infusion in adults with end stage renal disease (ESRD). Participants will be enrolled into two cohorts receiving either one (Cohort 1) or two or more (Cohort 2) obinutuzumab infusions. Bo...
What is the current status of trial NCT02586051?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2015-11-19. Estimated completion is 2018-11-26.
What conditions does trial NCT02586051 study?
This clinical trial studies the following conditions: Kidney Failure, Chronic.
What interventions are being tested in trial NCT02586051?
The interventions under investigation include: Obinutuzumab (DRUG), Intravenous Immunoglobulin (DRUG).
Who is sponsoring clinical trial NCT02586051?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02586051 being conducted?
This trial has 9 study locations across California, Maryland, Minnesota, Ohio, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Failure, Chronic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02586051's enrollment target sits among peer trials
24 19th of 23 higher than 4 of 23 other Kidney Failure, Chronic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Failure, Chronic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Empagliflozin in ESKD - A Feasibility Study
RECRUITING · Phase 1
-
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
RECRUITING · Phase 1
-
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)
COMPLETED · Phase 1
-
Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult Volunteers
COMPLETED · Phase 1
-
A Study to Evaluate JNJ-64565111 Pharmacokinetics and Safety in Adult Participants With Varying Degrees of Renal Function
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI